Ubs Group Ag Xeris Biopharma Holdings, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 283,252 shares of XERS stock, worth $971,554. This represents 0.0% of its overall portfolio holdings.

Number of Shares

283,252

Previous 163,639 73.1%

Holding current value

$971,554

Previous $368,000 119.29%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.06 - $2.96 $246,402 - $354,054	119,613 Added 73.1%	283,252 $807,000
Q2 2024 Aug 13, 2024	SELL	$1.7 - $2.45 $56,055 - $80,786	-32,974 Reduced 16.77%	163,639 $368,000
Q1 2024 May 13, 2024	BUY	$2.04 - $3.22 $126,890 - $200,287	62,201 Added 46.28%	196,613 $434,000
Q4 2023 Feb 09, 2024	BUY	$1.47 - $2.36 $88,158 - $141,533	59,972 Added 80.56%	134,412 $315,000
Q3 2023 Nov 09, 2023	BUY	$1.8 - $2.69 $127,949 - $191,213	71,083 Added 2117.46%	74,440 $138,000
Q2 2023 Aug 11, 2023	SELL	$1.82 - $2.98 $80,922 - $132,499	-44,463 Reduced 92.98%	3,357 $8,000
Q1 2023 May 12, 2023	BUY	$1.03 - $1.63 $22,358 - $35,382	21,707 Added 83.13%	47,820 $77,000
Q4 2022 Feb 08, 2023	BUY	$1.14 - $1.65 $12,614 - $18,257	11,065 Added 73.53%	26,113 $34,000
Q3 2022 Nov 10, 2022	BUY	$1.37 - $1.93 $16,427 - $23,142	11,991 Added 392.25%	15,048 $23,000
Q2 2022 Aug 10, 2022	SELL	$1.48 - $2.64 $69,995 - $124,856	-47,294 Reduced 93.93%	3,057 $5,000
Q1 2022 May 16, 2022	BUY	$2.0 - $2.87 $75,438 - $108,253	37,719 Added 298.6%	50,351 $129,000
Q4 2021 Feb 14, 2022	BUY	$1.8 - $2.93 $22,737 - $37,011	12,632 New	12,632 $37,000

Others Institutions Holding XERS

# of Institutions

143

Shares Held

60M

Call Options Held

148K

Put Options Held

45.7K

View Full List

About Xeris Biopharma Holdings, Inc.

Ticker XERS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,956,992
Market Cap $466M
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...

More about XERS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account